Aethlon Medical (AEMD)
Developer of the investigational Hemopurifier for virus and extracellular-vesicle removal.
Something off on this page? Send us feedback.
Develops the investigational Hemopurifier, a single-use plasma-filtration cartridge designed to remove enveloped viruses and extracellular vesicles. The pre-commercial business centers on an Australian oncology study and depends on clinical development, regulatory clearance, funding, and a future commercial channel.
Develops the investigational Hemopurifier, a single-use lectin-affinity plasmapheresis cartridge intended to bind and remove enveloped viruses and harmful extracellular vesicles from biological fluids. Its active program is an Australian safety, feasibility, and dose-finding study in advanced solid-tumor patients receiving pembrolizumab or nivolumab.
Operates a lean, pre-commercial model: clinical-study devices are manufactured in San Diego, while the wholly owned Australian subsidiary conducts current trial activity through hospitals, laboratories, and contract research organizations. The business has no approved product, sales force, or commercial revenue; future economics depend on clinical results, regulatory clearance, funding, reimbursement, and a commercial channel.
Development is concentrated in one investigational device, with limited-supplier inputs including the cartridge, lectin, and diatomaceous earth. FDA oversight governs clinical development, manufacturing, labeling, promotion, and post-market requirements, and the proposed alternate lectin supplier requires acceptance of an IDE supplement.
Company facts
Categories
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.9M · Total debt $255.1K · Total assets $6.2M · Shareholders' equity $5.2M
- Revenue
- $0
- Operating income
- −$1.6M
- Net income
- −$1.5M
No dividends on record.
| Institutions12 holders · as of Mar 31, 2026 | 2.69% | 14.2K shares | |
| Insiders4 holders · as of Jul 1, 2026 | 3.42% | 18.0K shares | |
| Otherremainder | 93.89% | 494.5K shares |
526.7K company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (711.1K in the company's Sep 3, 2026 report, 526.7K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Angela RossettiInsiderdirector | 1.00% | 5,241 | Form 4filed Apr 21, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.93% | 24,364 | 13Fas of Mar 31, 2026 |
Edward G. BroennimanInsiderdirector | 0.85% | 4,473 | Form 4filed Jul 1, 2026 ↗ |
Chetan ShahInsiderdirector | 0.79% | 4,168 | Form 4filed Jul 1, 2026 ↗ |
Nicolas GikakisInsiderdirector | 0.78% | 4,133 | Form 4filed Jul 1, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- CytoSorbents
Leading commercial peer in critical-care blood-purification cartridges.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aethlon Medical | $1.71 | −7.07% | $958.6K | — | — | — | — |
| CytoSorbents | $0.3398 | −11.88% | $24.1M | — | — | 0.6 | +0.2% |
| Median | — | — | 0.6 | +0.2% |